Sai Life Sciences, a Contract Research, Development and Manufacturing Organisation (CRDMO), has announced the completion of Phase-II of its new Production Block (PB-11) at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility in Bidar, India (Unit IV).

The Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. With the addition of Phase II (around 91 KL) in Q1 FY26, the combined capacity of the block now stands at approximately 200 KL, making it the single largest reactor volume block at the Bidar site. This expansion has taken the company’s total installed reactor capacity at the Bidar facility to around 700 KL.

Making the announcement, Krishna Kanumuri, CEO and Managing Director (MD), Sai Life Sciences, said, “Our clients are at the heart of everything we do. This expansion at Bidar is more than additional capacity — it is about giving our partners the confidence that we can scale with their needs, deliver reliably, and adapt to the increasing complexity of their programmes. By strengthening our large-scale API and intermediate manufacturing, we are enabling our clients to move faster, de-risk their supply chains and bring new medicines to market with greater assurance.”

PB-11 is a multi-purpose production block designed to handle large-scale commercial products. Sai Life Sciences’ Unit IV in Bidar is the company’s flagship manufacturing site, specialising in the production of APIs and advanced intermediates for markets such as the US, EU and Japan. It includes 12 production blocks with a combined capacity of around 700 KL, dedicated facilities for High-Potency APIs (HPAPIs), QC laboratories ensuring compliance and product integrity and advanced capabilities such as lyophilization, cryogenic reactions, high-pressure reactions and commercial-scale chromatography.

The facility has been inspected and approved by agencies including the USFDA, PMDA (Japan) and CDSCO (India).